Microbiome based Early Cancer Detection via Extracellular Vesicles

Our multidisciplinary team integrates expertise in molecular oncology, extracellular vesicle (EV) biology, multi-omics analysis, and AI-driven bioinformatics, with a strong focus on translational cancer research. The group has consolidated experience in:

• Liquid biopsy technologies, particularly EV-derived biomarkers in the cancer and microbiome discovery field

• Next-generation sequencing (NGS) and targeted cancer panels

• Proteomics (RPPA) and integrative multi-omics data analysis

• Advanced in vitro tumor models, including cancer stem cell-derived spheroids to mimic tumor heterogeneity

• Development and optimization of innovative high-sensitivity detection platforms

• Implementation of AI-supported analytical pipelines for biomarker discovery and predictive modelling in cancer and microbiome

• Cooperation and Management of partners for study participants' enrollment

The team operates in a clinically oriented framework, ensuring scalability, reproducibility, and regulatory compliance (GDPR-ready data integration), with the objective of accelerating the clinical translation of non-invasive diagnostic tools.